Biohit Oyj B (BIOBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biohit Oyj B (BIOBV) has a cash flow conversion efficiency ratio of 0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€600.00K ≈ $701.46K USD) by net assets (€14.90 Million ≈ $17.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Biohit Oyj B (BIOBV) total market value for the company's overall valuation and market capitalisation.
Biohit Oyj B - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Biohit Oyj B's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biohit Oyj B Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biohit Oyj B ranked by their cash flow conversion efficiency. Explore BIOBV cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lien Chang Electronic Enterprise Co Ltd
TW:2431
|
-0.008x |
|
Compumedics Ltd
AU:CMP
|
0.129x |
|
ABO Wind AG
XETRA:AB9
|
-0.283x |
|
Touax SCA
PA:ALPWG
|
0.059x |
|
Willowglen MSC Bhd
KLSE:0008
|
0.304x |
|
GFM Services Bhd
KLSE:0039
|
0.017x |
|
PetVivo Holdings Inc
NASDAQ:PETV
|
-0.438x |
|
Creative Realities Inc
NASDAQ:CREX
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Biohit Oyj B (2000–2025)
The table below shows the annual cash flow conversion efficiency of Biohit Oyj B from 2000 to 2025. View Biohit Oyj B share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €14.90 Million ≈ $17.42 Million |
€-700.00K ≈ $-818.37K |
-0.047x | -197.81% |
| 2024-12-31 | €12.20 Million ≈ $14.26 Million |
€586.00K ≈ $685.10K |
0.048x | -49.81% |
| 2023-12-31 | €9.43 Million ≈ $11.02 Million |
€902.00K ≈ $1.05 Million |
0.096x | -61.38% |
| 2022-12-31 | €7.46 Million ≈ $8.72 Million |
€1.85 Million ≈ $2.16 Million |
0.248x | +507.40% |
| 2021-12-31 | €7.30 Million ≈ $8.53 Million |
€-444.00K ≈ $-519.08K |
-0.061x | -2017.33% |
| 2020-12-31 | €8.70 Million ≈ $10.17 Million |
€-25.00K ≈ $-29.23K |
-0.003x | -150.46% |
| 2019-12-31 | €14.58 Million ≈ $17.05 Million |
€83.00K ≈ $97.04K |
0.006x | +197.28% |
| 2018-12-31 | €15.89 Million ≈ $18.58 Million |
€-93.00K ≈ $-108.73K |
-0.006x | +89.30% |
| 2017-12-31 | €17.24 Million ≈ $20.16 Million |
€-943.00K ≈ $-1.10 Million |
-0.055x | +76.07% |
| 2016-12-31 | €10.75 Million ≈ $12.57 Million |
€-2.46 Million ≈ $-2.87 Million |
-0.229x | +25.12% |
| 2015-12-31 | €10.31 Million ≈ $12.05 Million |
€-3.15 Million ≈ $-3.68 Million |
-0.305x | -12.65% |
| 2014-12-31 | €12.68 Million ≈ $14.82 Million |
€-3.44 Million ≈ $-4.02 Million |
-0.271x | -36.91% |
| 2013-12-31 | €22.45 Million ≈ $26.25 Million |
€-4.44 Million ≈ $-5.19 Million |
-0.198x | +20.99% |
| 2012-12-31 | €35.49 Million ≈ $41.49 Million |
€-8.89 Million ≈ $-10.39 Million |
-0.250x | -367.03% |
| 2011-12-31 | €52.85 Million ≈ $61.78 Million |
€4.96 Million ≈ $5.80 Million |
0.094x | -37.80% |
| 2010-12-31 | €13.00 Million ≈ $15.20 Million |
€1.96 Million ≈ $2.29 Million |
0.151x | -31.23% |
| 2009-12-31 | €12.75 Million ≈ $14.90 Million |
€2.80 Million ≈ $3.27 Million |
0.219x | +130.61% |
| 2008-12-31 | €12.49 Million ≈ $14.60 Million |
€1.19 Million ≈ $1.39 Million |
0.095x | +8.29% |
| 2007-12-31 | €11.84 Million ≈ $13.84 Million |
€1.04 Million ≈ $1.22 Million |
0.088x | +1078.15% |
| 2006-12-31 | €13.41 Million ≈ $15.68 Million |
€100.00K ≈ $116.91K |
0.007x | -82.44% |
| 2005-12-31 | €14.25 Million ≈ $16.66 Million |
€605.00K ≈ $707.31K |
0.042x | -73.18% |
| 2004-12-31 | €14.14 Million ≈ $16.53 Million |
€2.24 Million ≈ $2.62 Million |
0.158x | +158.63% |
| 2003-12-31 | €14.10 Million ≈ $16.49 Million |
€863.00K ≈ $1.01 Million |
0.061x | -46.71% |
| 2001-12-31 | €16.33 Million ≈ $19.10 Million |
€1.88 Million ≈ $2.19 Million |
0.115x | +110.71% |
| 2000-12-31 | €98.02 Million ≈ $114.60 Million |
€5.34 Million ≈ $6.25 Million |
0.055x | -- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more